Skip to main content

Table 3 Immunosuppression drugs prescribed (total for 2017–2021)

From: A population-based analysis of immunosuppression therapy after organ transplantation

 

Bavaria, outpatients

Nationwide, in- and outpatients

N (%)

€/patient

Total costs

N (%)

€/patient

Total costs

Glucocorticoids

7,467 (72.6%)

140

1,046,673

9,266 (78.7%)

170

1,577,736

 Prednisolone

6,357 (61.8%)

116

739,781

6,922 (58.8%)

132

916,067

 Prednisone

1,158 (11.3%)

84

96,987

1,926 (16.3%)

108

208,750

 Methylprednisolone

389 (3.8%)

159

62,010

1,328 (11.3%)

216

287,455

 Dexamethasone

879 (8.5%)

168

147,404

1,057 (9.0%)

157

165,423

 Cloprednol

1 (0.0%)

492

492

2 (0.0%)

20

41

Mycophenolic Acid

6,630 (64.5%)

7,883

52,266,731

6,919 (58.7%)

7,405

51,234,611

mTOR inhibitors

1,454 (14.1%)

26,808

38,979,315

1,834 (15.6%)

26,796

49,143,000

 Everolimus

895 (8.7%)

33,971

30,403,614

1,321 (11.2%)

31,946

42,200,100

 Sirolimus

586 (5.7%)

14,634

8,575,701

536 (4.5%)

12,953

6,942,900

Calcineurin Inhibitors

8,251 (80.2%)

17,850

147,282,666

9,221 (78.3%)

17,015

156,893,530

 Tacrolimus

6,324 (61.5%)

21,224

134,218,122

6,259 (53.1%)

22,228

139,127,575

 Ciclosporin

2,233 (21.7%)

5,851

13,064,544

3,359 (28.5%)

5,289

17,765,956

Azathioprine

546 (5.3%)

572

312,414

586 (5.0%)

562

329,254

Belatacept

80 (0.8%)

36,886

2,950,917

170 (1.4%)

29,356

4,990,483

  1. While the data are consistent within each cohort, a quantitative comparison has limitations because of differences in the number of patients involved and the duration of treatment
  2. Legend:mTOR mammalian target of rapamycin